Spinal Elements Announces First Clinical Use of the Lucent® 3D Lumbar Interbody System

What To Know

  • The resulting Lucent 3D implant is comprised of a strut-and-lattice structure with a bone graft chamber access lid designed to allow the surgeon to deliver a large amount of tightly packed graft inside the interbody structure, maximizing the amount of graft material available for fusion.
  • Spinal Elements announced FDA clearance of the Lucent 3D system in April of this year and expects to expand on Lucent 3D's graft containment concept in other clinical applications.

Spinal Elements, a spine technology company, today announced that the Lucent 3D Lumbar Interbody System has been successfully used in its first clinical cases with Dr. Thomas Noh, Neurosurgeon at Hawaii Pacific Health and Assistant Clinical Professor at the John A. Burns School of Medicine (JABSOM) at the University of Hawaii and Dr. Douglas H. Musser, D.O. at Youngstown Orthopedics Associates in Canfield, Ohio.

The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence. The resulting Lucent 3D implant is comprised of a strut-and-lattice structure with a bone graft chamber access lid designed to allow the surgeon to deliver a large amount of tightly packed graft inside the interbody structure, maximizing the amount of graft material available for fusion. Furthermore, when the access lid to the graft chamber is closed, the lid is designed to maximize surface area in contact with the vertebral endplates. Provided in both straight and curved designs, the interbody device is designed to be placed through an open or MIS posterior approach.

Dr. Noh commented, “The Lucent 3D Interbody is a novel and useful surgical option in my practice. The curved implant was easy to insert and helped to maintain lordosis. Knowing that there is tightly packed graft inside the cage provides additional confidence that a successful fusion will occur.”

Jason Blain, CEO of Spinal Elements, stated, “We are thrilled to share this technology with the surgical community. Lucent 3D’s novel design is meant to address subsidence and the amount of bone graft material available for fusion – two clinical challenges surgeons note exist with other 3D-printed interbody devices. We are pleased to offer additional innovative titanium interbody devices to our expansive and best-in-class product portfolio, adding to our long tradition of innovation in material science, novel designs, and leadership. We truly can answer any need for posterior lumbar fusion and continue to build on our procedural solutions.”

After finishing his first several Lucent 3D cases, Dr. Musser commented, “The design and structure of the Lucent 3D cage have provided a biologic containment area that has enabled me to place more graft material than traditional PLIF and TLIF cages. The Lucent 3D cage also has excellent visualization on both A/P and Lateral views when using fluoroscopy.”

Spinal Elements announced FDA clearance of the Lucent 3D system in April of this year and expects to expand on Lucent 3D’s graft containment concept in other clinical applications.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy